Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.51 |
| ▸ | MAPT | P10636 | 12/20 | 0.51 |
| ▸ | MEN1 | O00255 | 11/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.51 |
| ▸ | RECQL | P46063 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 6/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | APEX1 | P27695 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543001 | 1.00 | KMT2A (0.51) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14713029 | 0.89 | KMT2A (0.51) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14712870 | 0.89 | KMT2A (0.51) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14713052 | 0.86 | KMT2A (0.53) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14712962 | 0.86 | KMT2A (0.53) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14712995 | 0.84 | BCL2A1 (0.61) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14712869 | 0.84 | BCL2A1 (0.61) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL14712874 | 0.84 | ALDH1A1 (0.60) | KMT2AMAPTMEN1ALDH1A1RECQL | |
| SCHEMBL16543020 | 0.80 | MAPT (0.52) | KMT2AMAPTMEN1ALDH1A1POLB | |
| SCHEMBL14712882 | 0.79 | MEN1 (0.51) | KMT2AMAPTMEN1ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| WO-2013024447-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | KMT2A 2749/4885MAPT 2828/4885MEN1 2410/4885 |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAK1 | KMT2A 3262/4885MAPT 3272/4885MEN1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.